1 / 25

Lower the better; the case for glucose

Lower the better; the case for glucose. Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY. Epidemiology suggests high glucose is toxic. Blood glucose and CV risk. N = 17,869 men, aged 40–64 years; follow-up 33 years. 1.6. 1.2. CHD mortality (log hazard ratios)*.

allegra-parrish
Download Presentation

Lower the better; the case for glucose

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

  2. Epidemiology suggests highglucose is toxic

  3. Blood glucose and CV risk N = 17,869 men, aged 40–64 years; follow-up 33 years 1.6 1.2 CHD mortality (log hazard ratios)* 0.8 83 mg/dL 0.4 0.0 54 72 90 108 126 144 162 180 -0.4 OGTT blood glucose (mg/dL) Brunner EJ et al.Diabetes Care. 2006;29:26-31. *Relative to baseline group of all men with blood glucose <83 mg/dL

  4. Adjusted relative hazard of coronary heart disease in 1321 individuals without diabetes (A) and 1626 individuals with diabetes (B) Adjusted relative hazard of coronary heart disease in 1321 individuals without diabetes (A) and 1626 individuals with diabetes (B), adjusted for age, sex, and race and plotted on the log scale. All adjusted relative hazards are centered at hemoglobin A1c (HbA1c) = 5.2%, and the graphed lines are shown for the fifth to 95th percentiles of HbA1c level. The solid black line in A is from a single-knot linear spline model (knot at HbA1c = 4.6%). The dotted gray line is from a linear spline model with knots at the quintiles of HbA1c. In B, the solid black line is from a linear model; the gray dotted line is from a linear spline model with knots at the quintiles of HbA1c level. The normal range for HbA1c in persons without diabetes (4%-6%) is indicated by the dotted vertical lines in A. The current target for glycemic control in persons with diabetes (HbA1c = 7%) is indicated by the vertical dotted line in B. Arch Intern Med. 2005 Sep 12;165(16):1910-6.

  5. Diabetic milleu is a toxic soup with hyperglycemia, lipids, oxidative stress and combination of drugs….

  6. Oxidative stress Effect of postprandial hyperglycemia on the arterial wall Meal Hyperglycemia Hyperlipidemia Endothelial damage Atherosclerosis Haller H. Diab Res Clin Pract 1998;40:S43–S49.

  7. Adjusted Hazard Ratios for Self-Reported Diagnosed Diabetes and Coronary Heart Disease, Ischemic Stroke, and Death from Any Cause, According to the Baseline Glycated Hemoglobin Value. Selvin E et al. N Engl J Med 2010;362:800-811.

  8. BMJ. 2006 Jan 14;332(7533):73-8. Epub 2005 Dec 21

  9. Lowering glucose in a diabetic patient decreases macro and microvascular complications.

  10. Glucose Control Study Summary UKPDS • The intensive glucose control policy maintained a lower HbA1c by mean 0.9 % over a median follow up of 10 years from diagnosis of type 2 diabetes with reduction in risk of: • 12% for any diabetes related endpoint p=0.029 • 25% for microvascular endpoints p=0.0099 • 16% for myocardial infarction p=0.052 • 24% for cataract extraction p=0.046 • 21% for retinopathy at twelve years p=0.015 • 33% for albuminuria at twelve years p=0.000054

  11. Kaplan-Meier Curves for Four Prespecified Aggregate Clinical Outcomes Holman RR et al. N Engl J Med 2008;359:1577-1589

  12. DCCT/EDIC: Intensive glucose control reduces long-term CV risk N = 1441 with type 1 diabetes 0.12 0.12 42% (95% CI 9%–63%) P = 0.02 57% (95% CI 12%–79%) P = 0.02 0.10 0.10 0.08 0.08 Cumulative incidence of any first CV event Cumulative CV death, nonfatal MI, stroke Conventional 52 events 0.06 0.06 Conventional 25 events 0.04 0.04 Intensive 31 events Intensive 11 events 0.02 0.02 0 0 0 5 10 15 20 0 5 10 15 20 Time (years) Time (years) DCCT/EDIC Study Research Group.N Engl J Med. 2005;353:2643-53.

  13. Glucose Control at Baseline and during Follow-up, According to Glucose-Control Strategy The ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-2572

  14. Cumulative Incidences of Events, According to Glucose-Control Strategy The ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-2572

  15. Normoglycemia does not necessarily mean increased hypoglycemia

  16. Hypoglycemia is a side effect of treatment not of good metabolic control

  17. Annual Rates of Severe Hypoglycemia According to Treatment Assignment and Adverse Clinical Outcomes among Patients with Severe Hypoglycemia. Zoungas S et al. N Engl J Med 2010;363:1410-1418.

  18. How about ACCORD ?

  19. Kaplan–Meier Curves for the Primary Outcome and Death from Any Cause. The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008;358:2545-2559.

  20. Spline curves displaying the risk of all-cause mortality with the two treatment strategies over the range of average A1C from 6.0 to 9.0%. The curves represent the linear part of the proportional hazards models derived from values for intervals of average A1C from model 3. For clarity, the figure omits values <6 and >9%; ∼5% of deaths are excluded from this plot at the lower end and also at the higher end of the A1C range, but these data are included in the models. The bold orange line represents the intensive treatment strategy group, the bold blue line represents the standard group, and the finer colored lines represent the 95% CIs for each group.

  21. Can we predict future improvement in glycaemic control?.Diabetic Medicine25 (2), 170-173 2008 Change in HbA1c by group; two subsets can be created based on likely improvement

  22. It is inappropriately intensive treatment “not goodglycemic control” which increase the risk.

  23. We have to individualize diabetes treatment. Most of the time side effects are a result of confectionary treatments.

  24. So we should achive as low HbA1c as possible in an individual patient without causing hypoglycemia and weight gain. We have the tools.

More Related